Preferred partner for RAS blockers

Adalat GITS-telmisartan (TALENT study)

Adalat GITS–telmisartan: early and sustained BP control in hypertensive patients at high cardiovascular risk

TALENT was a multicentre, randomised, double-blind 16-week trial (with an optional 8-week extension period). Hypertensive patients at high cardiovascular risk (n=327) received telmisartan 80 mg/Adalat GITS 20 mg either as monotherapy or in combination; patients in the monotherapy group were switched to combination therapy after 8 weeks.1

Optimum BP control was achieved as early as two weeks in TALENT, demonstrating the BP-lowering efficacy of the combination of Adalat GITS and telmisartan. TALENT shows that early BP control can be achieved more effectively by initiating treatment using the combination of Adalat GITS and telmisartan, compared with starting on one drug and then adding the second.1

Mancia G, et al. J Hypertens 2011;29:600-9.
*p<0.05 vs Adalat-GITS monotherapy
†p<0.05 vs telmisartan monotherapy

Combination treatment with Adalat GITS and telmisartan provides greater and earlier 24-h BP control compared with the individual components in monotherapy.1

Mancia G, et al. J Hypertens 2011;29:600-9.

Adalat CR - candesartan (NICE-Combi Study)

Adalat CR–candesartan: superior BP control vs up-titrated candesartan monotherapy

The Nifedipine and Candesartan Combination (NICE-Combi) study selected patients (n=258) with essential hypertension who had not achieved target BP with a baseline treatment of candesartan 8 mg/day for 8 weeks.2

These patients were randomised to receive either:
  • Candesartan 8 mg/day plus Adalat CR 20 mg/day
  • Candesartan 12 mg/day2

BP lowering was significantly greater in the combination therapy group, compared to up-titrated monotherapy (−12.1/−8.7 mmHg vs −4.1/−4.6 mmHg, p<0.0001).2

Hasebe N, et al. J Hypertens 2005;23:445-53.
*p<0.05 compared with baseline (Week 8)
†p<0.05 between treatment groups.

Significantly more patients in the combination therapy group achieved their age-specific BP targets.2

Hasebe N, et al. J Hypertens 2005;23:445-53.
Target BP was specified according to age.
Age <60 years: target BP<130/85 mmHg.
Age 60–69 years: target BP <140/90 mmHg.
Age ≥70 years: target BP <150/90 mmHg.

Adalat GITS - candesartan (DISTINCT I study)

Adalat GITS–candesartan: superior, dose-dependent BP lowering vs monotherapy

The DISTINCT I study was designed to determine the dose-response of various combinations of Adalat GITS and candesartan compared with respective monotherapies and placebo in patients (n=1381) with Grade 1 and 2 essential hypertension, over an 8-week treatment period.3

Adalat GITS and candesartan in combination significantly (p<0.0001) contributed to BP lowering.3 The greatest BP lowering effect was seen with Adalat GITS 60 mg + candesartan 32 mg (−23.4/−16.2 mmHg).3

Kjeldsen SE, et al. J Hypertens 2014;32:2488–2498.

Adalat CR - valsartan (ADVANCE-Combi study)

Adalat CR–valsartan: reduces BP more effectively than amlodipine–valsartan

The Adalat CR and Valsartan Cost-Effectiveness Combination (ADVANCE-Combi) study randomised hypertensive patients (n=505) into two treatment groups:4
  • Adalat CR plus valsartan
  • Amlodipine plus valsartan

The study used four medication regimens, and all patients started with Regimen 1. If target BP was not achieved after 4 weeks, treatment shifted to the next regimen.

After 16 weeks of treatment, SBP and DBP lowering was significantly greater in the Adalat CR group, compared to the amlodipine group (p<0.05).4
Saito I, et al. Hypertens Res 2006;29:789-96.
*p<0.05 vs baseline; †p<0.05 between treatment groups.
The rate of target BP achievement (primary efficacy endpoint) was significantly higher in the Adalat CR group (P<0.001). This effect was observed irrespective of age.4
Saito I, et al. Hypertens Res 2006;29:789-96.
*p<0.001 between groups.

Adalat GITS - valsartan (ADVISE study)

Adalat GITS–valsartan: superior BP control vs valsartan monotherapy in Asian patients with hypertension

ADVISE was a 12-week, multicentre, randomised, open-label study which enrolled Asian patients with hypertension (n=359) who had previously been inadequately controlled with valsartan 80 mg.5

Patients were randomised to receive either:5
  • Adalat GITS 30 mg plus valsartan 80 mg, or
  • Valsartan 160 mg

BP control rates were significantly higher with combination therapy.5 Overall control rates for combination therapy vs monotherapy at Week 12 were 71.2% vs 55.5% (P=0.0024).5

The superior efficacy of combination therapy vs monotherapy was sustained when the population was stratified according to cardiovascular risk*.5

Ke Y-N, et al. Cardiovasc Ther 2012; 30:326-32.
*Cardiovascular risk was defined according to criteria set out in the ESC/ESH 2007 Guidelines.6

Adalat GITS - lisinopril

A four week study enrolling patients with essential hypertension (n= 51 randomized patients) compared:
  • Lisinopril 20 mg
  • Adalat GITS 30 mg
  • Lisinopril 20 mg plus Adalat GITS 30 mg
The combination therapy provided significantly greater reductions in clinic BP and ambulatory BP (ABP), compared to either monotherapy (p<0.01).7
Taddei S, et al. J Cardiovasc Pharmacol 2003;41:579-85.
*p<0.01 between combination and single therapy; four-week treatment period.

References

  1. Mancia G, et al. J Hypertens 2011;29:600-9.
  2. Hasebe N, et al. J Hypertens 2005;23:445-53.
  3. Kjeldsen, SE et al. J Hypertens 2014;32:2488–2498.
  4. Saito I, et al. Hypertens Res 2006;29:789-96.
  5. Ke Y-N, et al. Cardiovasc Ther 2012; 30:326-32.
  6. Mancia G, et al. J Hypertens 2007;25:1105-87.
  7. Taddei S, et al. J Cardiovasc Pharmacol 2003;41:579-85.